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Abstract Desmosine (DES) is an elastin-derived, cross-link amino acid, which is notmetabolized; hence, its urinary
levels re£ect elastin breakdown.We hypothesized that elastin degradation should increase as a result of increased lung
in£ammationduringan acute exacerbationof COPDand should decrease afterrecovery.Totestthishypothesiswemea-
sured DES in three urine samples from nine COPD subjects during the ¢rst 5 days of an acute exacerbation and at 2
months after recovery.We alsomeasured forced expiratory volume in1sec (FEV1) tomonitor the e¡ects of the exacer-
bation on ventilatory function.Themean (SD) FEV1was 45 (15)% predicted during the exacerbation and 57?8 (16)% pre-
dicted 2monthslater (P=0?00001).Themean (SD) DES excretionwas 25 3 (9) mg g-1creatinine atday1;23 5 (9) atday 3
and 24 (9) atday 5 of the exacerbation.Themean (SD) urinary DES excretion 60 days afterdischargewas 20?9 (7) mg g-1
creatinine (P=0?049) in comparisonwiththemeanofthe three acute-phase values.The size ofthe increase in desmosine
excretion during exacerbation is small, 3?2mg g-1 creatinine or 16% of the recovery desmosine value.We conclude that
there is a small but statistically signi¢cant increase in lung elastin breakdown in the bodyduring an acute exacerbation of
COPD.r2001Elsevier Science Ltd
doi:10.1053/rmed.2001.1224, available online athttp://www.idealibrary.comon
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Chronic obstructive pulmonary disease (COPD) is a de-
structive lung disorder characterized by chronic, partly
reversible air£ow limitation and the presence of chronic
bronchitis or emphysema. Degradation of extracellular
matrix components, mainly elastin, due to an imbalance
between proteinases and their naturally occurring inhi-
bitors is a key pathological feature of emphysema (1). Ex-
cess elastin degradation in the body results in excretion
in the urine of the elastin-derived amino acids, desmo-
sine (DES) (2). This cross-linked amino acid is unique to
mature elastin and is notmetabolized in the body. Urin-
ary excretion of DES has been reported to be higher in
patients with COPD, and in current smokers with nor-
mal lung function (3,4) than in never-smoking controls.Received 23 July 2001, accepted in revised form19 September 2001and
published online10 December 2001.
Correspondence should be addressed to:Dr Maurizio Luisetti,
Laboratorio di Biochimica eGenetica, IRCCSPoliclinico SanMatteo,Via
Taramelli 5, 27100 Pavia, Italy.Fax: +39 0382 502269; E-mail:
m.luisetti@smatteo.pv.itWerecently applied a new separation technique, high-
performance capillary electrophoresis (HPCE), in itsmi-
cellar electrokinetic chromatographic (MEKC) modality,
to the quanti¢cation of urinary DES in subjects with a
variety of chronic destructive lung diseases, including
subjects with COPD, disseminated bronchiectasis of un-
knownorigin, pulmonaryemphysema associatedwith in-
herited de¢ciency of a1-anti-trypsin (AAT) and cystic
¢brosis (4).
In a preliminary study, we noted that COPD patients
with exacerbations excreted more elastin cross-links
than patients with stable COPD (4).We reasoned that
elastin degradation increaseddue to increased in£amma-
tion in the lungs during an acute exacerbation of COPD,
which resulted in increasedurinaryDES excretion. If this
were so, urinaryDESvalues shoulddecrease after recov-
ery from the exacerbation. To test this hypothesis we
collected three urine samples from each of nine COPD
subjects during the ¢rst 5 days of an acute exacerbation
andwe collected a fourthurine sample at 2months after
recovery.We alsomeasured forced expiratory volume in
1 sec (FEV1) serially during the study to monitor the
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study shows a small, but statistically signi¢cant decrease
in urinary DES excretion at 2 months, in comparison
with values during the acute exacerbation.This is accom-
paniedby a signi¢cant increase in FEV1at 2 months com-
pared to the acute exacerbation.
MATERIALSANDMETHODS
Design of the study
This investigation was designed as a longitudinal study,
whichwas approvedby thehospital’s Ethical Committee.
All patients gave their informed consent prior to enter-
ing the study.
Patients
We enrolled nine consecutive patients admitted to the
Clinica di Malattie dell’Apparato Respiratorio, San Mat-
teo Hospital, because of acute exacerbation of COPD.
These subjects belong to a cohort of patients regularly
seen in the outpatient clinic of the same department, in
whom the diagnosis of COPDhadbeenpreviously estab-
lished according to ATS criteria (5). All patients were
male former smokers.
De¢nition ofexacerbation and selection of patients
Following the criteria of Anthonisen et al. (6), we diag-
nosed an acute exacerbation of COPD by the presence
of two or three of the symptoms of increased dyspnoea,
increased sputum volume and development of sputum
purulence. The initial assessment of patients was per-
formed in the emergency room (ER) of San Matteo Hos-
pital. In our study we enrolled only patients admitted
because of a moderately severe exacerbation, thus
excluding patients with a mild exacerbation who were
immediately discharged from the ER and treated
at home. We also excluded those with a severe
exacerbation, requiring mechanical or non-invasive
ventilation (7). Patients who had had another episode
of acute exacerbation within the previous three
months or had already received oral corticosteroidsTABLE 1. Characteristics of the patientswith acute exacebation
No Sex Age
(yrs)
Height
(cm)
Weight
(kg)
9 Male 69 (5) 164 (7) 71 (5)
*Data are expressed asmean (SD).Six subjectshadthree ofthe
two ofthe three symptoms.
wPost-bronchodilatordata obtainedwithin the fourth dayof hoat the time of admission were excluded from the
study.
Patients’assessment and treatment
At the time of hospitalization, the patients were sub-
mitted to routine assessment, including blood gas analy-
sis, chest X-ray (to exclude pneumonia) and sputum
culture. The patients received aminophylline every 12 h,
methylprednisolone 30 mg every 24 h i.v., nebulizations
of oxitropium bromide and beclomethasone every 8 h,
low £ow oxygen supplementation via nasal cannula and
an 8-day course of oral amoxycillin/clavulanic acid 1 g
every12 h (in one case the antibiotic therapy was chan-
ged to i.v. cefotaxime1g every12 h after 48 h because of
isolation from sputum of K. pneumoniae resistant to
amoxycillin/clavulanic acid). All associated conditions
were treated appropriately. Pulmonary functions tests
were performed as soon as the general and respiratory
condition of the patients allowed, but in all cases within
the ¢rst 4 days of the hospital admission.Table1reports
the clinical characteristics of the patients enrolled in the
study.
Outcome ofthe exacerbation and follow-up
Thepatients’dischargewas decidedon thebasis ofremis-
sion of symptoms and signs used to de¢ne the episode of
exacerbation. Still-needed treatments were swithched
from the intravenous to the oral route; oralmethylpred-
nisolone was tapered and de¢nitively withdrawn within
3 weeks after discharge. All patients were telephoned
every 2 weeks to inquire about their condition. A fol-
low-up examination was performed 60 days after dis-
charge. Stability of their respiratory state was checked
by a brief questionnaire and pulmonary function tests
were performed.
Timing ofurine collection
Threeurine sampleswere collected during the hospitali-
zation: one within the ¢rst 24 h (T1), the others on the
third (T3) and ¢fth (T5) days. At the 2-month follow-up
visit, patients delivered a urine sample collected during
the12 h prior to the appointment (T60).of COPD*
Smokinghistory
(pack-years)
FEV1
w
(% pred.)
FVC
(%w pred.)
35 (7) 45 (5) 59 (2)
de¢ning symptomsof an exacerbation (6); three subjectshad
spitalization.
FIG. 1. Time course of desmosine (^ ^ )^ and FEV1 (^ )^. Points
represent mean values (SD). The shaded area represents the
mean71 96 SD of urinary DES in12 healthy never-smokers (4).
NotethatmeanvaluesofDESinthis studyare abovetherangeof
normalatalltimepoints.Valuesony-axis aremg g-1forDESand%
predicted for FEV1
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Chemicals
Sodiumphoshate (used as a background electrolyte) was
purchased from Bio-Rad (Richmond,CA,U.S.A).Doubly
distilled water was obtained from a Millipore (Bedford,
MA,U.S.A.) Milli-Q puri¢cation system. All other chemi-
cals were of analytical grade and were used without
further puri¢cation.
Urine collection and treatment
Urine sampleswere collected into sterile plastic bottles,
starting in themorning, until a volume of100 mlwas ob-
tained, whichwas stored atÿ201Cuntil processed.Each
samplewas concentratedunder reducedpressureusing a
heated rotary evaporator (501C). A sample of urine (0?8
ml)was thenultracentrifuged atroom temperaturewith
microconcentrators Microcon 30 (Millipore) and trans-
ferred to hydrolysis pyrex tubes, evaporated to dryness
and hydrolysed in vacuo with HCI 6 N at 1061C for 24 h.
Hydrolysed sampleswere lyophilized and the residuedis-
solved in deionisedwater (repeated twice in order to re-
move HCI totally). Finally, samples were taken up with
0?4 ml of distilled water and submitted to HPCE. The
content of DESwas expressed as mg g-1creatinine.
Capillary electrophoretic instrumentation and running
conditions
All runs were performed using a Bio-Rad Biofocus 3000
system equipped with a high-speed UV-Vis scanning de-
tector. Fused silica capillaries of 57 cm (50 cm e¡ective
length frominlet to detector) 50mm IDwere obtained
from Beckman (Palo Alto, CA, U.S.A.). The procedure
followedwas essentially as describedpreviously (8),with
themodi¢cation subsequently adopted (4).
Statistical analysis
Data are presented as mean and standard deviation (SD).
Normality of data distribution was assessed by the Sha-
piro ^Wilk test. Repeated measure MANOVAwas used
to test for statistically signi¢cant changes over time for
DES and t-test for paired data of FEV1. A P-value of less
than 0?05 was considered to be statistically signi¢cant.
All tests were two-sided. Analyses were performed by
the software STATA (StataCorp, 1999. Stata Statistical
Software release 6?0 College Station,TX,U.S.A.).
RESULTS
Urinary excretion of elastin cross-links changed little
during the ¢rst 5 days of hospital admission: mean (SD)
DES excretion was 25?3 (9) mg g-1 creatinine at T1, 23?5(9) at T3 and 24 (90) at T5. All comparisons were non-sig-
ni¢cant.
Pulmonary function tests, performed on the fourth
dayof the admission, revealedmoderate air£owobstruc-
tion. Mean (SD) FEV1 was 45715% predicted and the
mean (SD) forced vital capacity (FVC) was 59 (12)% pre-
dicted.
All subjects enrolled in this studyrecovered from their
acute exacerbation of COPD. Symptoms subsided
promptly, and patients were discharged after a mean
(SD) hospital stay of 7 (2) days. After discharge, patients
were telephoned every 2 weeks, to gain information
about their condition and adherence to treatment. In
particular, oral corticosteriods werewithdrawn from all
subjects within 3 weeks after discharge.
At the follow-up appointment, 60 days afterdischarge,
all subjectswere in stable clinical condition andnone had
experienced a further episode of acute exacerbation, as
determined by the questionnaire. Pulmonary function
tests showed a mean (SD) FEV1 of 57?8 (16)% predicted
and amean (SD) FVCof 73 (13)% predicted.The di¡erence
in FEV1 values between exacerbation and follow-up was
highly signi¢cant (P=0  00001).
The mean (SD) urinary excretion of DES, as deter-
mined at T60, was 20?9 (7) mg g
-1 creatinine. The di¡er-
ence between T60 and the mean of the three values
obtained during the exacerbationwas statistically signif-
icant (P=0?049). Figure 1 shows a plot of urinary excre-
tion of DES and of FEV1during the study period.
DISCUSSION
Emphysema is one of the critical elements for de¢ning
COPD. Although the precise details of the events in the
alveolar walls are poorly understood, there are three
main hypotheses of its pathogenesis. These are more
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elastase imbalance hypothesis (1), the oxidant^anti-oxi-
dant imbalance hypothesis (9) and the infection hypoth-
esis (10).This studydoes not specifybetween these three
hypotheses. It suggests that excess elastin degradation
occurs in an acute exacerbation of COPD because of in-
creased in£ammation in the lungs. Elastin degradation
couldbe due to elastase^anti-elastase imbalance, tooxi-
dant^anti-oxidant imbalance in the lungs or to infection;
we do not distinguish among in£ammation due to
viruses, bacteria or chemical irritation, as from urban
air pollution.
Previous studies have shown that urinary DES is ele-
vated in subjects with COPD in comparison to both
never-smokers and smokerswithout air£ow obstruction
(3).Note in Fig.1thatmeanvalues ofDES in this study are
above therange of normal at all timepoints.Wehoped in
the current study to determinewhether elastin degrada-
tion was increased during an acute exacerbation of
COPD as compared with the stable state. Accordingly,
wemeasuredcross-linkexcretion during the acute phase
of an acute exacerbation (days 1^5). Since baseline urin-
ary DES values were not available on our subjects, we
assumed that urinary DES/IDES excretion during the
chronic phase (day 60) would be a reasonable re£ection
of the pre-exacerbation, stable state.We also measured
the FEV1 during the acute and late phases of the study.
We reasoned that the FEV1would be decreased during
the acute phase of the study as a result of increased in-
£ammation in the lungs and should be restored during
the chronic phase as the in£ammation accompanying
the exacerbation subsided. Two recent reports support
the behaviour of the FEV1 in this condition. Hill et al. (11)
compared 11 patients with homozygous AAT de¢ciency
and 11 control patients with COPD and normal AAT le-
vels during an exacerbation. All patients received14 days
of antibiotic therapy; none receivedoral corticosteroids.
The concentrations of sputum myeloperoxidase activity
(which servedas an assessmentof neutrophil in£ux), spu-
tum elastase activity, IL-8 and LTB4 concentrations all fell
signi¢cantly by the third day of the exacerbation andhad
reached a nadir by day14. At presentation, sputum elas-
tase acivity, IL-8 and LTB4 concentrations were lower in
the control COPD patients than in the AAT-de¢cient
COPD patients; the time course of improvementwas si-
milar in the two groups. In the AAT-de¢cient group,
mean (SE) peak expiratory £ow rate was 236?4 (41?4)
l min-1 at presentation and rose by11?9 per cent of base-
line (Po0?005) by day14. Peak £ow rate results were si-
milar in the usual COPD group.
Bhowmik et al. (12) studied ventilatory function, spu-
tum cells and cytokines in 57 patients with moderate to
severe COPD during the stable state and during an ex-
acerbation of their disease. Median values of IL-6, IL-8,
total cell count, total neutrophils, total eosinophils and
total lymphocytes were higher during exacerbation thanin the stable state, but the only signi¢cant di¡erence
(Po0?05) was for IL-6. The mean (SD) FEV1 was 1?07
(0?26) I during the stable state and fell to 0?99 (0?31) l
(P40?05) at the onset of the exacerbation. The mean
peak expiratory £ow rate data, 239 (78) l min-1 and 225
(73) l min-1, respectively, were statistically signi¢cantly
di¡erent (Po0?05).
By 60 days after discharge from hospital, all of our pa-
tients showed sustained clinical and functional recovery
from the acute exacerbation, as witnessed by the ab-
sence of symptoms and marked improvement in FEV1.
Thus, we have shown in this study that therewas a small,
but statistically signi¢cant decrease in urinary DES va-
lues between the acute and chronic phases of the study
and these changes were accompained by an increase in
ventilatory function. Hill et al. (11) showed stability of in-
£ammatory parameters by day 14. Indeed in their data,
values of these parameters were higher at day 28 than
at day14.
It is widely accepted that recurrent exacerbations ac-
celerate airway and parenchymal damage in COPD (13),
we noted only a modest increase in urinary DES excre-
tion between the acute and chronic phasesF3?2 mg g-1
creatinine or 16% of the chronic phase value. However,
over a period of years, even slight increases in elastin de-
gradation during an exacerbation may cause a sustained
injury. Itremains to be determinedhow long the increase
in urinary DES excretion lasts after an exacerbation and
whether there is indeed a complete recovery to baseline
excretion rate.
Previous papers have failed to demonstrate a correla-
tion between urinary DES levels and FEV1measured at a
single time point in a group of patients (4,14). These ob-
servations are not surprising since ventilatory function
at any one point in time is determined by the amount of
elastin degradation that has occurred in the past over an
extended period of timeFa period of years. On the
other hand, it makes perfectly good sense that over a
period of 2 months after an acute exacerbation of
COPD, changes in lung in£ammation, urinary cross-link
excretion and ventilatory function shouldmirror one an-
other.
In mice, after an acute elastolytic injury, more than
half of the desmosine-containing peptides removed from
the lungs are sequestered by the kidney and then slowly
released into the urine over a period of several days (15).
The role of the kidney in the kinetics of elastolysis in
stable or acute conditions in humans is undetermined.
However, we speculate that in our study, any sequestra-
tion of DES in the kidney should have been over by 60
days after the acute exacerbation.
Because of the great expense of evaluating new drugs
for COPD using rate of change of FEV1 as the outcome
variable (16), there ismuch interest in the possible use of
measurementof urinaryelastin cross-links as a surrogate
marker of elastin degradation in the lungs for drug
114 RESPIRATORYMEDICINEdevelopment inCOPD (4,17,18). A recentreport failed to
demonstrate that short-term AATreplacement therapy
in AAT-de¢cient patients was able to reduce elastin
breakdown (18) despite baseline elevation of urinary
DES levels in these patients. However, the failure of an
e¡ectcouldhavebeendue to a lowdose of augmentation
therapy with AATor elastolysis could have been due to
macrophage-derived metalloelastase, which is not inac-
tivated by AAT.
The changes in urinary DES between the acute and
chronic phases of the study were small and thevariability
of the DESvalues is large (coe⁄cient of variation for the
sixT1, T3, T5 and T60 groups was about 35%). Hence, the
data reported here must be considered preliminary and
larger studies should be done.Nevertheless, our results
raise the question of whether anti-elastase or anti-oxi-
dant drugs might be administered to protect the lungs
during an acute excacerbation. While studies of elas-
tases, oxidants or in£ammatory mediators in sputum or
bronchoalveolar lavage might be used to determine the
e⁄cacy of such drugs, urinary DESmeasurements are a
more de¢nitive measure of lung destruction and should
be used as well.
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